Swedish Orphan Biovitrum AB (SOBI.ST)
-Stockholm 40.20 
0.40(1.01%) 11:30AM EDT
| Prev Close: | 39.80 |
|---|
| Open: | 40.30 |
|---|
| Bid: | 40.20 |
|---|
| Ask: | 40.30 |
|---|
| 1y Target Est: | 24.64 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 39.70 - 40.70 |
|---|
| 52wk Range: | 21.60 - 45.50 |
|---|
| Volume: | 139,327 |
|---|
| Avg Vol (3m): | 261,712 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in SEK.
Headlines
- Sobi gets FDA approval to manufacture substance for Kineret® with partner Boehringer IngelheimThomson Reuters ONE(Tue, Jun 11)
- Sobi appoints Mats-Olof Wallin as permanent Chief Financial OfficerThomson Reuters ONE(Fri, May 17)
- Resolutions from Sobi's Annual General Meeting (AGM)Thomson Reuters ONE(Fri, Apr 26)
- Q1 2013 Biovitrum AB Earnings Release - 02:00 am ETCCBN(Fri, Apr 26)
- Sobi publishes Report for the First Quarter 2013Thomson Reuters ONE(Fri, Apr 26)
- Invitation - Presentation of Sobi's first quarter results 2013Thomson Reuters ONE(Wed, Apr 17)
- Sobi appoints Mats-Olof Wallin as interim Chief Financial OfficerThomson Reuters ONE(Mon, Apr 8)
- Sobi publishes Annual ReportThomson Reuters ONE(Fri, Apr 5)
- Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)Thomson Reuters ONE(Mon, Mar 25)
- Sobi and Savient Pharmaceuticals Announce Co-Promotion Agreement for Kineret® (anakinra) in the U.S.PR Newswire(Tue, Feb 19)
- New Phase 3 Data Reinforce Long-Lasting Protection from Bleeding for Patients with Hemophilia A and BBusiness Wire(Fri, Feb 8)
- Biogen Hemophilia A Therapy Helps in Fewer Injectionsat Bloomberg(Wed, Oct 31)
- Biogen Says Hemophilia B Medicine Controlled Bleedingat Bloomberg(Wed, Sep 26)
Reports
- No Reports available for SOBI.ST at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-11)
: | N/A |
|---|
| Quarterly EPS Est
(Dec-11)
: | N/A |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
No business summary available forSOBI.ST.